{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-024914","form_type":"8-K","ticker":"ABCL","cik":"0001703057","company_name":"AbCellera Biologics Inc.","filed_at":"2022-06-30T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.903836+00:00","generated_at":"2026-06-24T22:05:10.592033+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lilly to supply additional 150K doses of AbCellera's bebtelovimab for ~$275M","bullets":["Eli Lilly modified agreement with U.S. government for 150,000 additional doses of bebtelovimab at ~$275M.","Delivery begins immediately and completes by August 5, 2022; option for 350,000 more doses by Sep 14, 2022.","Bebtelovimab maintains neutralization against Omicron variants BA.2.12.1 and BA.4/BA.5, plus all known variants.","Existing supply plus new purchase expected to meet U.S. demand through late August 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-024914","json":"https://secwatch.observer/filing/0001564590-22-024914.json","markdown":"https://secwatch.observer/filing/0001564590-22-024914.md","text":"https://secwatch.observer/filing/0001564590-22-024914.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703057/000156459022024914/0001564590-22-024914-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703057/000156459022024914/abcl-8k_20220629.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T22:05:10.592033+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}